Latest Headlines

Latest Headlines

Recipharm teams with Astimex on CDMO deal

Astimex Pharma has picked Recipharm as its development and manufacturing partner on a new drug.

Novasep lays out $39M for new API plant

Novasep is continuing to expand its contract manufacturing capabilities, now spending $38.8 million to build a commercial API plant in Mourenx, France.

Sanofi Pasteur MSD recalls typhoid vaccine

Sanofi Pasteur MSD, a vaccine joint venture of Sanofi and Merck, recalled 16 batches--or 88%--of its Typhim Vi vaccine because of concerns about effectiveness.

Mayne Pharma snags CDMO Metrics for $120M

Australia's Mayne Pharma has agreed to buy Metrics, a contract developer and manufacturer of niche drugs, in a deal worth up to $120 million.

Olympus Biotech jumps into CMO game

Seeing a boost in demand for biologics, Olympus Biotech is offering CMO services out of its Lebanon, NH, plant. 

Flu vaccine manufacturers face steep odds

As flu season approaches, vaccines companies are working against the odds to market their influenza vaccines. Last year, the overall U.S. vaccination rate was about 42%--a far cry from the target rates of 80% for people ages 6 months to 65 years and 90% for those older than 65.

Cedarburg Hauser bets on API boom with plant expansion

Wisconsin CMO Cedarburg Hauser is expanding its API-production capabilities, responding to what it says is booming demand for drug components around the world.

Boehringer Ingelheim shutters U.S. API plant

Boehringer Ingelheim says it's coping with excess capacity in its CMO network, and will shut down one of its three API-producting plants in the U.S. as a result.

CMOs move toward disposable manufacturing tech

The CMO units of Merck KGaA and Boehringer Ingelheim are investing in single-use, disposable technolgies in their manufacturing processes, saying the move will help their clients get drugs on the market faster than traditional methods.

Catalent targets South Korea with CTC Bio partnership

Catalent Pharma Solutions has teamed up with South Korea's CTC Bio to attract clients looking to market solid oral dose and controlled-release products in the U.S. and Europe.